Role of metformin in functional endometrial hyperplasia and polycystic ovary syndrome involves the regulation of MEG3/miR‑223/GLUT4 and SNHG20/miR‑4486/GLUT4 signaling

Liu,Jie; Zhao,Yangchun; Chen,Long; Li,Ruilan; Ning,Yumei; Zhu,Xiuzhi

doi:10.3892/mmr.2022.12734

Role of metformin in functional endometrial hyperplasia and polycystic ovary syndrome involves the regulation of MEG3/miR‑223/GLUT4 and SNHG20/miR‑4486/GLUT4 signaling

Authors:
- Jie Liu
- Yangchun Zhao
- Long Chen
- Ruilan Li
- Yumei Ning
- Xiuzhi Zhu
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310000, P.R. China, Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310000, P.R. China, PCR Laboratory, Department of Laboratory Medicine, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310000, P.R. China, Department of Gynecology, Zhejiang Maternal and Child Health and Reproductive Health Center, Hangzhou, Zhejiang 310000, P.R. China
Published online on: May 12, 2022 https://doi.org/10.3892/mmr.2022.12734
Article Number: 218
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metformin (MET) can effectively treat endometrial hyperplasia (EH), and the expression of glucose transporter type 4 insulin‑responsive (GLUT4) is closely associated with the development of EH. The present study aimed to verify the effect of MET in functional EH and polycystic ovary syndrome (PCOS). H&E staining was performed to analyze the severity of EH, and immunohistochemistry was performed to evaluate the expression of GLUT4 in the endometrium of PCOS rats. Reverse transcription‑quantitative PCR was used to calculate the expression of long non‑coding (lnc)RNA‑maternally expressed gene 3 (MEG3), lncRNA‑small nucleolar RNA host gene 20 (SNHG20), GLUT4 mRNA, microRNA (miR)‑223 and miR‑4486. Sequence analysis and luciferase assays were performed to explore the regulatory relationship among certain lncRNAs, miRNAs and target genes. EH in PCOS rats was efficiently inhibited by MET administration. The increased expression of GLUT4 in PCOS rats was attenuated by MET treatment. Moreover, the expression levels of lncRNA‑MEG3 and lncRNA‑SNHG20 were significantly inhibited in the endometrium of PCOS rats. MET treatment also showed remarkable efficiency in restoring the expression of lncRNA‑MEG3 and lncRNA‑SNHG20. Meanwhile, the expression levels of miR‑223 and miR‑4486 were notably elevated in the endometrium of PCOS rats, while MET treatment reduced the expression of miR‑223 and miR‑4486 in PCOS rats. Furthermore, a luciferase assay confirmed the inhibitory relationship between miR‑223 and lncRNA‑MEG3/GLUT4 expression, as well as between miR‑4486 and lncRNA‑SNHG20/GLUT4 expression. GLUT4 knockdown restored the decreased viability of HCC‑94 cells induced by overexpression of lncRNA‑MEG3. To conclude, MET exhibited a therapeutic effect in the treatment of EH by modulating the lncRNA‑MEG3/miR‑223/GLUT4 and lncRNA‑SNHG20/miR‑4486/GLUT4 signaling pathways. This work provides mechanistic insight into the development of EH.

View Figures

View References

1	Norman RJ, Dewailly D, Legro RS and Hickey TE: Polycystic ovary syndrome. Lancet. 370:685–697. 2007. View Article : Google Scholar
2	Ehrmann DA: Polycystic ovary syndrome. N Engl J Med. 352:1223–1236. 2005. View Article : Google Scholar : PubMed/NCBI
3	Homburg R: Management of infertility and prevention of ovarian hyperstimulation in women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 18:773–788. 2004. View Article : Google Scholar
4	Shang K, Jia X, Qiao J, Kang J and Guan Y: Endometrial abnormality in women with polycystic ovary syndrome. Reprod Sci. 19:674–683. 2012. View Article : Google Scholar
5	Mioni R, Mozzanega B, Granzotto M, Pierobon A, Zuliani L, Maffei P, Blandamura S, Grassi S, Sicolo N and Vettor R: Insulin receptor and glucose transporters mRNA expression throughout the menstrual cycle in human endometrium: A physiological and cyclical condition of tissue insulin resistance. Gynecol Endocrinol. 28:1014–1018. 2012. View Article : Google Scholar
6	Mozzanega B, Mioni R, Granzotto M, Chiarelli S, Xamin N, Zuliani L, Sicolo N, Marchesoni D and Vettor R: Obesity reduces the expression of GLUT4 in the endometrium of normoinsulinemic women affected by the polycystic ovary syndrome. Ann N Y Acad Sci. 1034:364–374. 2004. View Article : Google Scholar
7	Carvajal R, Rosas C, Kohan K, Gabler F, Vantman D, Romero C and Vega M: Metformin augments the levels of molecules that regulate the expression of the insulin-dependent glucose transporter GLUT4 in the endometria of hyperinsulinemic PCOS patients. Hum Reprod. 28:2235–2244. 2013. View Article : Google Scholar : PubMed/NCBI
8	Emons G, Beckmann MW, Schmidt D and Mallmann P; Uterus commission of the Gynecological Oncology Working G, : New WHO classification of endometrial hyperplasias. Geburtshilfe Frauenheilkd. 75:135–136. 2015. View Article : Google Scholar : PubMed/NCBI
9	Antonsen SL, Ulrich L and Høgdall C: Patients with atypical hyperplasia of the endometrium should be treated in oncological centers. Gynecol Oncol. 125:124–128. 2012. View Article : Google Scholar
10	Kurman RJ, Kaminski PF and Norris HJ: The behavior of endometrial hyperplasia. A long-term study of ‘untreated’ hyperplasia in 170 patients. Cancer. 56:403–412. 1985. View Article : Google Scholar : PubMed/NCBI
11	Cheung AP: Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol. 98:325–331. 2001. View Article : Google Scholar
12	Jung CH, Ro SH, Cao J, Otto NM and Kim DH: mTOR regulation of autophagy. FEBS Lett. 584:1287–1295. 2010. View Article : Google Scholar
13	Brosius J: Waste not, want not-transcript excess in multicellular eukaryotes. Trends Genet. 21:287–288. 2005. View Article : Google Scholar
14	Mercer TR, Dinger ME and Mattick JS: Long non-coding RNAs: Insights into functions. Nat Rev Genet. 10:155–159. 2009. View Article : Google Scholar
15	Rapicavoli NA, Qu K, Zhang J, Mikhail M, Laberge RM and Chang HY: A mammalian pseudogene lncRNA at the interface of inflammation and anti-inflammatory therapeutics. Elife. 2:e007622013. View Article : Google Scholar : PubMed/NCBI
16	Hu G, Gong AY, Wang Y, Ma S, Chen X, Chen J, Su CJ, Shibata A, Strauss-Soukup JK, Drescher KM and Chen XM: LincRNA-Cox2 promotes late inflammatory gene transcription in macrophages through modulating SWI/SNF-mediated chromatin remodeling. J Immunol. 196:2799–2808. 2016. View Article : Google Scholar
17	Paladini L, Fabris L, Bottai G, Raschioni C, Calin GA and Santarpia L: Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res. 35:1032016. View Article : Google Scholar : PubMed/NCBI
18	Shao R, Li X, Feng Y, Lin JF and Billig H: Direct effects of metformin in the endometrium: A hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. J Exp Clin Cancer Res. 33:412014. View Article : Google Scholar : PubMed/NCBI
19	Shen ZQ, Zhu HT and Lin JF: Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol. 112:465–467. 2008. View Article : Google Scholar
20	Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, Meyer LA, Soliman PT, Lu KH, Ramirez PT, et al: Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol. 131:109–116. View Article : Google Scholar
21	Li X, Guo YR, Lin JF, Feng Y, Billig H and Shao R: Combination of Diane-35 and metformin to treat early endometrial carcinoma in PCOS women with insulin resistance. J Cancer. 5:173–181. 2014. View Article : Google Scholar : PubMed/NCBI
22	Stanosz S: An attempt at conservative treatment in selected cases of type I endometrial carcinoma (stage I a/G1) in young women. Eur J Gynaecol Oncol. 30:365–369. 2009.
23	Li X, Feng Y, Lin JF, Billig H and Shao R: Endometrial progesterone resistance and PCOS. J Biomed Sci. 21:22014. View Article : Google Scholar
24	Cui P, Li X, Wang X, Feng Y, Lin JF, Billig H and Shao R: Lack of cyclical fluctuations of endometrial GLUT4 expression in women with polycystic ovary syndrome: Evidence for direct regulation of GLUT4 by steroid hormones. BBA Clin. 4:85–91. 2015. View Article : Google Scholar : PubMed/NCBI
25	Li X, Cui P, Jiang HY, Guo YR, Pishdari B, Hu M, Feng Y, Billig H and Shao R: Reversing the reduced level of endometrial GLUT4 expression in polycystic ovary syndrome: A mechanistic study of metformin action. Am J Transl Res. 7:574–586. 2015.PubMed/NCBI
26	Zhang Y, Hu M, Meng F, Sun X, Xu H, Zhang J, Cui P, Morina N, Li X, Li W, et al: Metformin ameliorates uterine defects in a rat model of polycystic ovary syndrome. EBioMedicine. 18:157–170. 2017. View Article : Google Scholar : PubMed/NCBI
27	Zhang Y, Liu X, Bai X, Lin Y, Li Z, Fu J, Li M, Zhao T, Yang H, Xu R, et al: Melatonin prevents endothelial cell pyroptosis via regulation of long noncoding RNA MEG3/miR-223/NLRP3 axis. J Pineal Res. 64:2018. View Article : Google Scholar
28	Liu J, Cheng LG and Li HG: LncRNA SNHG20 promoted the proliferation of glioma cells via sponging miR-4486 to regulate the MDM2-p53 pathway. Eur Rev Med Pharmacol Sci. 23:5323–5331. 2019.
29	Zhang Y, Sun X, Sun X, Meng F, Hu M, Li X, Li W, Wu XK, Brännström M, Shao R and Billig H: Molecular characterization of insulin resistance and glycolytic metabolism in the rat uterus. Sci Rep. 6:306792016. View Article : Google Scholar : PubMed/NCBI
30	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals, . Guide for the Care and Use of Laboratory Animals. 8th edition. National Academies Press (US); Washington, DC: 2011
31	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
32	Markowicz-Piasecka M, Sikora J, Szydlowska A, Skupien A, Mikiciuk-Olasik E and Huttunen KM: Metformin-a future therapy for neurodegenerative diseases: Theme: Drug discovery, development and delivery in Alzheimer's disease guest editor: Davide Brambilla. Pharm Res. 34:2614–2627. 2017. View Article : Google Scholar : PubMed/NCBI
33	Pernicova I and Korbonits M: Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 10:143–156. 2014. View Article : Google Scholar
34	Miyoshi N, Wagatsuma H, Wakana S, Shiroishi T, Nomura M, Aisaka K, Kohda T, Surani MA, Kaneko-Ishino T and Ishino F: Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q. Genes Cells. 5:211–220. 2000. View Article : Google Scholar : PubMed/NCBI
35	Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR and Klibanski A: A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab. 88:5119–5126. 2003. View Article : Google Scholar : PubMed/NCBI
36	Menon AG, Rutter JL, von Sattel JP, Synder H, Murdoch C, Blumenfeld A, Martuza RL, von Deimling A, Gusella JF and Houseal TW: Frequent loss of chromosome 14 in atypical and malignant meningioma: Identification of a putative ‘tumor progression’ locus. Oncogene. 14:611–616. 1997. View Article : Google Scholar : PubMed/NCBI
37	Itoyama T, Chaganti RS, Yamada Y, Tsukasaki K, Atogami S, Nakamura H, Tomonaga M, Ohshima K, Kikuchi M and Sadamori N: Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: A study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. Blood. 97:3612–3620. 2001. View Article : Google Scholar : PubMed/NCBI
38	Zhang D, Cao C, Liu L and Wu D: Up-regulation of LncRNA SNHG20 predicts poor prognosis in hepatocellular carcinoma. J Cancer. 7:608–617. 2016. View Article : Google Scholar : PubMed/NCBI
39	Li C, Zhou L, He J, Fang XQ, Zhu SW and Xiong MM: Increased long noncoding RNA SNHG20 predicts poor prognosis in colorectal cancer. BMC Cancer. 16:6552016. View Article : Google Scholar : PubMed/NCBI
40	Aravinthan A, Challis B, Shannon N, Hoare M, Heaney J and Alexander GJM: Selective insulin resistance in hepatocyte senescence. Exp Cell Res. 331:38–45. 2015. View Article : Google Scholar : PubMed/NCBI
41	Li Y, Li C, Yang M, Shi L, Tao W, Shen K, Li X, Wang X, Yang Y and Yao Y: Association of single nucleotide polymorphisms of miRNAs involved in the GLUT4 pathway in T2DM in a Chinese population. Mol Genet Genomic Med. 7:e9072019. View Article : Google Scholar : PubMed/NCBI
42	Li H, Li Y, Liu D, Sun H and Liu J: miR-224 is critical for celastrol-induced inhibition of migration and invasion of hepatocellular carcinoma cells. Cell Physiol Biochem. 32:448–458. 2013. View Article : Google Scholar : PubMed/NCBI
43	Sha M, Ye J, Zhang LX, Luan ZY, Chen YB and Huang JX: Celastrol induces apoptosis of gastric cancer cells by miR-21 inhibiting PI3K/Akt-NF-κB signaling pathway. Pharmacology. 93:39–46. 2014. View Article : Google Scholar : PubMed/NCBI
44	Zhang X, Xue XC, Wang Y, Cao FF, You J, Uzan G, Peng B and Zhang DH: Celastrol reverses palmitic acid-induced insulin resistance in HepG2 cells via restoring the miR-223 and GLUT4 pathway. Can J Diabetes. 43:165–172. 2019. View Article : Google Scholar : PubMed/NCBI